Trials / Terminated
TerminatedNCT00351715
Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients
Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients: a Phase II Multicenter, Open Label, Feasibility Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- AHS Cancer Control Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the outpatient population before conducting an appropriately powered phase III study. Thus the primary purpose of this study is to determine the proportion of patients who are successfully titrated to an optimal dose of sublingual (Under the tongue) methadone and then studied at that optimal dose with successive episodes of breakthrough pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sublingual Methadone |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2006-07-13
- Last updated
- 2019-10-21
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00351715. Inclusion in this directory is not an endorsement.